Lutetium Lu-177 Vipivotide Tetraxetan is used for treating metastatic castration-resistant prostate cancer in adult patients with PSMA-positive tumors who have failed previous treatments with androgen receptor inhibition and taxane-based chemotherapy. It was first introduced by Novartis Pharmaceuticals Corp in its drug Pluvicto on Mar 23, 2022.

Lutetium Lu-177 Vipivotide Tetraxetan Patents

Given below is the list of patents protecting Lutetium Lu-177 Vipivotide Tetraxetan, along with the drug name that holds that patent and the company name owning that drug.

Download patent list as spreadsheet

Get the complete list right in your inbox!

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Pluvicto	US11951190	Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer	Nov 12, 2035	Novartis
Pluvicto	US10398791	Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer	Oct 17, 2034	Novartis
Pluvicto	US10406240	PSMA binding ligand-linker conjugates and methods for using	Aug 15, 2028	Novartis
Pluvicto	US11318121	PSMA binding ligand-linker conjugates and methods for using	Aug 15, 2028	Novartis

Add above patents to watchlist

Lutetium Lu-177 Vipivotide Tetraxetan's Family Patents

Full family tree